Nordklint, A. K. http://orcid.org/0000-0003-1448-618X
Almdal, T. P.
Vestergaard, P.
Lundby-Christensen, L.
Boesgaard, T. W.
Breum, L.
Gade-Rasmussen, B.
Sneppen, S. B.
Gluud, C.
Hemmingsen, B.
Jensen, T.
Krarup, T.
Madsbad, S.
Mathiesen, E. R.
Perrild, H.
Tarnow, L.
Thorsteinsson, B.
Vestergaard, H.
Lund, S. S.
Eiken, P.
Funding for this research was provided by:
Jascha Fonden
Kaptajnløjtnant Harald Jensens og Hustrus Fond
A & J C Tvergaards Fond
Osteoporoseforeningen
Inge og Per Refshalls Forskningslegat
Dansk Knoglemedicins Selskab
Nordsjællands hospitals forskningspulje
Region Hovedstaden
Article History
Received: 26 March 2018
Accepted: 9 July 2018
First Online: 19 July 2018
Compliance with ethical standards
: A signed informed consent form was obtained from all participants. Both the original trial and the current sub-study were approved by the regional ethical committee (region of Copenhagen journal number H-D-2007-112), the Danish Medicines Agency (journal number 2612-3648), reported to the Danish Data Protection Agency (NOH-2015-034) and registered with ExternalRef removed (NCT00657943). The study was conducted in accordance with the Helsinki Declaration and guidelines of Good Clinical Practice.
: Azra Karahasanovic Nordklint owns shares in Novo Nordisk A/S. Pia Eiken is an advisory board member for Amgen and Eli Lilly, and on the speakers’ bureau for Amgen and Eli Lilly, and own shares in Novo Nordisk A/S. Louise Lundby Christensen owns shares in Novo Nordisk A/S. Thomas Almdal owns shares in NovoNordisk A/S. Søren S. Lund has previously published his opinion about the clinical effects of metformin treatment. Søren S. Lund owns shares in Novo Nordisk A/S and shares in dynamically traded investment funds, which may own stocks from pharmaceutical companies. Søren S. Lund has reported former employment at Steno Diabetes Center, which is a diabetes hospital and academic institution previously owned by Novo Nordisk. Søren S. Lund is now employed at Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. Søren S. Lund’s contribution was his alone and does not necessarily reflect the official position of Boehringer Ingelheim; Trine W. Boesgaard owns shares in Novo Nordisk A/S. Trine W. Boesgaard has reported former employment at Steno Diabetes Center, which is a diabetes hospital and academic institution previously owned by Novo Nordisk. Trine W. Boesgaard is now employed at Novo Nordisk. Trine W Boesgaard’s contribution was hers alone and does not necessarily reflect the official position of Novo Nordisk. Peter Vestergaard, Leif Breum, Birthe Gade-Rasmussen, Simone B Sneppen, Christian Gluud, Bianca Hemmingsen, Tonny Jensen, Thure Krarup, Sten Madsbad, Elisabeth R Mathiesen, Hans Perrild, Lise Tarnow, Birger Thorsteinsson and Henrik Vestergaard have no conflicts of interest to declare.